Will the FDA approve gedatolisib for advanced breast cancer?

gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before X 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application, NDA, or Biologics License Application, BLA, For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA, sNDA, or supplemental BLA, sBLA, for the sp